Akeso, Inc. (HKG:9926)

Hong Kong · Delayed Price · Currency is HKD

107.30

+5.30 (5.20%)

Mar 6, 2026, 4:08 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Research, Development, Production and Sale of Biopharmaceutical Products	2.12B	4.53B	837.66M	225.63M		70.88M
Research, Development, Production and Sale of Biopharmaceutical Products Growth	-53.08%	440.35%	271.26%	-		2408.10%
Total	2.12B	4.53B	837.66M	225.63M		70.88M
Total Growth	-53.08%	440.35%	271.26%	-		2408.10%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Mainland China	1.88B	1.59B	837.66M	97.03M		-
Mainland China Growth	17.85%	90.24%	763.33%	-		-
United States of America (USA)	243.64M	2.93B	-	128.60M		70.88M
United States of America (USA) Growth	-91.69%	-	-	-		-
Other Regions	2.26M	1.20M	-	-		-
Other Regions Growth	87.53%	-	-	-		-
Total	2.12B	4.53B	837.66M	225.63M		70.88M
Total Growth	-53.08%	440.35%	271.26%	-		2408.10%

Source: S&P Global Market Intelligence.